Insmed Incorporated (INSM)
Company Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.
The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Country | United States |
Founded | 1988 |
IPO Date | Jun 1, 2000 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 912 |
CEO | William H. Lewis J.D., M.B.A. |
Contact Details
Address: 700 Us Highway 202/206 Bridgewater, New Jersey 08807 United States | |
Phone | 908-977-9900 |
Website | insmed.com |
Stock Details
Ticker Symbol | INSM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001104506 |
CUSIP Number | 457669307 |
ISIN Number | US4576693075 |
Employer ID | 54-1972729 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
William H. Lewis J.D., M.B.A. | President, Chief Executive Officer and Chairman |
Sara M. Bonstein M.B.A. | Chief Financial Officer |
Roger Adsett M.B.A. | Chief Operating Officer |
John Drayton Wise M.B.A. | Chief Commercial Officer |
Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer |
Brian K. Kaspar Ph.D. | Chief Scientific Officer |
Eleanor Barisser | Associate Director of Investor Relations |
Michael Alexander Smith J.D. | Chief Legal Officer and Corporate Secretary |
Mandy Fahey | Executive Director of Corporate Communications |
S. Nicole Schaeffer M.B.A. | Chief People Strategy Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 11, 2024 | 8-K | Current Report |
Feb 22, 2024 | 8-K | Current Report |
Feb 22, 2024 | 424B5 | Filing |
Feb 22, 2024 | 10-K | Annual Report |
Feb 16, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |